Hepatitis C, Chronic

Infectious Diseases
73
Pipeline Programs
12
Companies
50
Clinical Trials
1 recruiting
6
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
14
4
22
0
13
20
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
11100%
+ 81 programs with unclassified modality

On Market (6)

Approved therapies currently available

Roche
COPEGUSApproved
ribavirin
Roche
oral2002
GS
HARVONIApproved
ledipasvir and sofosbuvir
Gilead Sciences
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]oral2019
VP
INCIVEKApproved
telaprevir
Vertex Pharmaceuticals
oral2011
M&
PEGINTRONApproved
peginterferon alfa-2b
Merck & Co.
2001
M&
SYLATRONApproved
peginterferon alfa-2b
Merck & Co.
2001
M&
VICTRELISApproved
boceprevir
Merck & Co.
oral2011

Competitive Landscape

12 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
26 programs
3
6
5
Patients receiving Sof/VelPhase 4
Patients receiving Sof/VelPhase 41 trial
Sofosbuvir/Velpatasvir 400 MG-100 MG Oral TabletPhase 41 trial
sofosbuvir/velpatasvirPhase 4Small Molecule
sofosbuvir/velpatasvirPhase 4Small Molecule1 trial
+21 more programs
Active Trials
NCT01457768Completed570Est. Apr 2018
NCT04952207Unknown300Est. Aug 2021
NCT05401136Unknown1,000Est. Dec 2023
+13 more trials
M&
Merck & Co.RAHWAY, NJ
16 programs
2
2
3
3
PEG-IFN alfa-2bPhase 41 trial
Pegylated interferon alfa 2bPhase 41 trial
ZEPATIER 50Mg-100Mg TabletPhase 41 trial
BoceprevirPhase 3Small Molecule1 trial
Peginterferon alfa-2bPhase 31 trial
+11 more programs
Active Trials
NCT00727077Terminated3Est. Jun 2007
NCT01641666Withdrawn0Est. Sep 2016
NCT01590225Withdrawn0Est. Aug 2021
+21 more trials
Roche
RocheSTAVANGER NORWAY, Norway
13 programs
3
2
4
Peginterferon alfa-2aPhase 41 trial
Peginterferon alfa-2aPhase 41 trial
boceprevirPhase 4Small Molecule1 trial
peginterferon alfa-2a [Pegasys]Phase 41 trial
Pegylated-interferon alfa-2aPhase 31 trial
+8 more programs
Active Trials
NCT01070550Completed4,680Est. Jul 2011
NCT01609049Completed1,496Est. Jun 2015
NCT01280656Completed660Est. Jun 2013
+20 more trials
VP
6 programs
2
1
1
2
1
TelaprevirPhase 3Small Molecule1 trial
TelaprevirPhase 3Small Molecule
Telaprevir and SofosbuvirPhase 2Small Molecule1 trial
VCH-759Phase 1/21 trial
ALS-002158Phase 11 trial
+1 more programs
Active Trials
NCT01554085Terminated78Est. Sep 2012
NCT01590407Completed71Est. Feb 2013
NCT00389298Completed36Est. Jun 2007
+2 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
4 programs
1
1
ombitasvir, paritaprevir/r, dasabuvir + ribavirinPhase 41 trial
ABT-450/rPhase 2
Evaluating the Chain of Addiction Care (CAC)N/A
GeneXpert HCV VL Fingerstick testN/A
Active Trials
NCT02461745Completed200Est. May 2017
Bristol Myers Squibb
3 programs
1
1
DCV/ASV/BCVPhase 41 trial
PEG-rIL-29Phase 21 trial
Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted N/A1 trial
Active Trials
NCT02969668Completed326Est. Dec 2019
NCT01001754Unknown600Est. May 2012
NCT02292966Withdrawn0Est. Jun 2016
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
17 programs
5
2
4
6
BI 201335Phase 31 trial
BI 201335Phase 31 trial
BI 207127-placebo: 8-week treatmentPhase 31 trial
PegIFN/RBVPhase 31 trial
PegIFN/RBVPhase 31 trial
+12 more programs
Active Trials
NCT02176525Completed75
NCT00905632Completed75
NCT00793793Completed96Est. Jan 2011
+14 more trials
PharmaEssentia
PharmaEssentiaMA - Burlington
2 programs
1
1
PEGASYS 180 µg Q1WPhase 21 trial
P1101 + RibavirinPhase 11 trial
Active Trials
NCT04774107CompletedEst. Jul 2022
NCT01587586CompletedEst. Nov 2016
Ionis Pharmaceuticals
2 programs
1
1
ISIS 14803Phase 21 trial
ISIS 14803, peginterferon alfa, ribavirinPhase 1/21 trial
Active Trials
NCT00062816Completed22Est. Jan 2004
NCT00035945CompletedEst. May 2004
Abbott
AbbottABBOTT PARK, IL
1 program
1
ABT-450/rPhase 22 trials
Active Trials
NCT01685203Completed316Est. Feb 2015
NCT01306617Completed50Est. Oct 2012
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
ViramidinePhase 21 trial
Active Trials
NCT00305383TerminatedEst. May 2007
Transgene
TransgeneFrance - Illkirch-Graffenstaden
1 program
1
MVA-HCVPhase 11 trial
Active Trials
NCT00529321CompletedEst. Sep 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Gilead SciencesSofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
Merck & Co.ZEPATIER 50Mg-100Mg Tablet
Gilead Sciencessofosbuvir/velpatasvir
Gilead SciencesPatients receiving Sof/Vel
Bristol Myers SquibbDCV/ASV/BCV
AbbVieombitasvir, paritaprevir/r, dasabuvir + ribavirin
Merck & Co.PEG-IFN alfa-2b
Rocheboceprevir
Merck & Co.Pegylated interferon alfa 2b
RochePegylated Interferon Alfa-2a
RochePeginterferon alfa-2a
Merck & Co.Peginterferon alfa-2b
Merck & Co.Peginterferon alfa-2b
Merck & Co.Peginterferon alfa-2b
Merck & Co.Peginterferon alfa-2b

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 13,975 patients across 50 trials

NCT05140941Gilead SciencesSofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet

Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy

Start: Apr 2022Est. completion: Jun 2026100 patients
Phase 4Recruiting
NCT03797066Merck & Co.ZEPATIER 50Mg-100Mg Tablet

ATTIC - Access To Treat in the Community

Start: Mar 2019Est. completion: Nov 202013 patients
Phase 4Terminated
NCT03235154Gilead Sciencessofosbuvir/velpatasvir

A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic

Start: Oct 2017Est. completion: Sep 201911 patients
Phase 4Completed
NCT03018353Gilead SciencesPatients receiving Sof/Vel

Curing HCV in Incarcerated Patients

Start: Mar 2017Est. completion: Jun 2018100 patients
Phase 4Unknown
NCT02292966Bristol Myers SquibbDCV/ASV/BCV

Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism

Start: Jul 2015Est. completion: Jun 20160
Phase 4Withdrawn
NCT02461745AbbVieombitasvir, paritaprevir/r, dasabuvir + ribavirin

Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO

Start: Jun 2015Est. completion: May 2017200 patients
Phase 4Completed
NCT01606800Merck & Co.PEG-IFN alfa-2b

Efficacy and Safety of Short Course Therapy With Peginterferon Alpha-2b (PEG-IFN Alfa-2b) and Ribavirin (RBV) for Chronic Hepatitis C (Genotype 4) Participants Achieving a Rapid Virological Response at Week 4 of Treatment (MK-8908B-059)

Start: Jan 2013Est. completion: Jan 201545 patients
Phase 4Terminated
NCT01591460Rocheboceprevir

A Triple Combination Therapy Study of Boceprevir, Pegasys and Copegus in Previously Untreated Patients With Genotype 1 Chronic Hepatitis C

Start: Aug 2012Est. completion: Jun 2014165 patients
Phase 4Completed
NCT01364090Merck & Co.Pegylated interferon alfa 2b

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3

Start: Jun 2012Est. completion: Oct 201593 patients
Phase 4Completed
NCT00641654RochePegylated Interferon Alfa-2a

Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin

Start: Jan 2007Est. completion: Dec 200975 patients
Phase 4Terminated
NCT00353418RochePeginterferon alfa-2a

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection

Start: Jun 2006Est. completion: Apr 2009415 patients
Phase 4Completed
NCT00687544Merck & Co.Peginterferon alfa-2b

Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)

Start: Dec 2005Est. completion: Sep 200811 patients
Phase 4Terminated
NCT00202839Merck & Co.Peginterferon alfa-2b

Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)

Start: Mar 2005Est. completion: Jul 2008160 patients
Phase 4Completed
NCT00255008Merck & Co.Peginterferon alfa-2b

Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)

Start: Mar 2005Est. completion: Dec 2007121 patients
Phase 4Terminated
NCT00255034Merck & Co.Peginterferon alfa-2b

Effects of 48 Weeks Versus 24 Weeks of Therapy With Peg-Intron/Ribavirin in Patients With Chronic Hepatitis C, Genotype 3 (Study P04143)(TERMINATED)

Start: Feb 2005Est. completion: Jun 2008146 patients
Phase 4Terminated
NCT00087633Rochepeginterferon alfa-2a [Pegasys]

PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.

Start: Oct 2004Est. completion: Oct 2008115 patients
Phase 4Completed
NCT00948220RochePeginterferon alfa-2a

Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C

Start: Jul 2003Est. completion: Mar 200826 patients
Phase 4Completed
NCT02641379RochePeginterferon alfa-2a

A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)

Start: May 2003Est. completion: Nov 2013737 patients
Phase 4Completed
NCT02263079RochePegylated Interferon Alfa-2a

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

Start: Jun 2014Est. completion: Jan 202062 patients
Phase 3Completed
NCT01641666Merck & Co.Peginterferon alfa-2b

Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)

Start: May 2014Est. completion: Sep 20160
Phase 3Withdrawn
NCT01945294Merck & Co.Boceprevir

Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)

Start: Oct 2013Est. completion: Nov 2015257 patients
Phase 3Completed
NCT01858961Boehringer IngelheimBI 201335

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Start: May 2013Est. completion: Jul 20160
Phase 3Withdrawn
NCT01590225Merck & Co.Peginterferon alfa-2b

Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)

Start: Jan 2013Est. completion: Aug 20210
Phase 3Withdrawn
NCT01732796Boehringer IngelheimRibavirin

IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1

Start: Dec 2012Est. completion: Jan 2015470 patients
Phase 3Completed
NCT01728324Boehringer IngelheimBI 207127-placebo: 8-week treatment

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Start: Nov 2012Est. completion: Jan 2015496 patients
Phase 3Completed
NCT01608737Boehringer IngelheimPegIFN/RBV

A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection

Start: Sep 20120
Phase 3Withdrawn
NCT01544920Merck & Co.peg-Interferon alfa-2a

Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)

Start: May 2012Est. completion: May 2015737 patients
Phase 3Completed
NCT01459913Vertex PharmaceuticalsTelaprevir

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype

Start: Nov 2011Est. completion: Jan 2014239 patients
Phase 3Terminated
NCT01405560Merck & Co.Vaniprevir

Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)

Start: Sep 2011Est. completion: Mar 201342 patients
Phase 3Completed
NCT01399619Boehringer IngelheimPegIFN/RBV

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

Start: Sep 2011Est. completion: Jun 2014310 patients
Phase 3Completed
NCT01405937Merck & Co.Vaniprevir

Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)

Start: Aug 2011Est. completion: Mar 201351 patients
Phase 3Completed
NCT01358864Boehringer IngelheimBI 201335

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Start: Jun 2011Est. completion: May 2014678 patients
Phase 3Completed
NCT01023035Merck & Co.Peginterferon alfa-2b

Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)

Start: Dec 2009Est. completion: Oct 2011687 patients
Phase 3Completed
NCT00910624Merck & Co.Peginterferon alfa-2b

Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)

Start: Jun 2009Est. completion: Dec 2012168 patients
Phase 3Completed
NCT00800735RochePegylated-interferon alfa-2a

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Start: Apr 2009Est. completion: Mar 201230 patients
Phase 3Completed
NCT00623428Rochepeginterferon alfa-2a

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Start: Jun 2008Est. completion: May 2012235 patients
Phase 3Completed
NCT00761735Merck & Co.Peginterferon alfa-2b

5 Year Long-term Follow up in Pediatric Participants Who Received PegIntron Plus Rebetol in P02538 Part I (P02538 Pt 2)

Start: Jul 2007Est. completion: Jan 201394 patients
Phase 3Completed
NCT00687219Merck & Co.Peginterferon alfa-2b

Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)

Start: Jun 2007Est. completion: Oct 2010102 patients
Phase 3Completed
NCT00686881Merck & Co.Peginterferon alfa-2b

Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)

Start: Dec 2006Est. completion: Feb 2011261 patients
Phase 3Terminated
NCT00686790Merck & Co.Peginterferon alfa-2b

Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)

Start: Dec 2005Est. completion: May 200968 patients
Phase 3Completed
NCT00441584Merck & Co.Peginterferon alfa-2b

The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)

Start: Jul 2005Est. completion: Jun 2008117 patients
Phase 3Terminated
NCT02791256RochePeginterferon alfa-2a

A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6

Start: Jun 2005Est. completion: Jun 200823 patients
Phase 3Terminated
NCT00104052Merck & Co.Peginterferon alfa-2b

Study of PEG-Intron Plus REBETOL in Pediatric Subjects With Chronic Hepatitis C (Study P02538 Part 1)

Start: Feb 2005Est. completion: Nov 2007107 patients
Phase 3Completed
NCT01095835RochePegylated Interferon Alfa-2a

A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Start: Feb 2005Est. completion: Jan 2010131 patients
Phase 3Completed
NCT00221286RochePegylated Interferon Alfa-2a

Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients

Start: Sep 2004Est. completion: Jan 20072 patients
Phase 3Terminated
NCT00154869RochePeginterferon alfa-2a

Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C

Start: Jun 2004Est. completion: Aug 2007320 patients
Phase 3Unknown
NCT00081770Merck & Co.Peginterferon alfa-2b

Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)

Start: Mar 2004Est. completion: Nov 20074,469 patients
Phase 3Completed
NCT00302081Merck & Co.Peginterferon alfa-2b

Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)

Start: Aug 2003Est. completion: Apr 2008696 patients
Phase 3Completed
NCT00811967Merck & Co.Peginterferon alfa-2b

Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)

Start: Feb 2003Est. completion: May 200650 patients
Phase 3Terminated
NCT00049842Merck & Co.Peginterferon alfa-2b

Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)

Start: Oct 2002Est. completion: Oct 2009540 patients
Phase 3Completed

Related Jobs in Infectious Diseases

Executive Director, Global Medical Expert HIV Prevention - GMA Virology & Inflammation

Gilead Sciences
United States - Field
17h ago
$317K - $411K/yr

Sr. Engineer, Process Systems (Contract)

VaxCyte
Visp, Valais, Switzerland
20h ago

Director, Health Economics & Outcomes Research (HEOR)

VaxCyte
San Carlos, California, United States
22h ago
$242K - $282K/yr

Director U.S. Meningococcal Marketing

Pfizer
United States - New York - New York City
Yesterday
$177K - $294K/yr

Senior Manager, Contract Account Performance Specialist, Contract Strategy

Pfizer
Remote
Yesterday
$124K - $207K/yr

Scientist, Computational Vaccine Design

Metaphore Biotechnologies
Cambridge, MA USA
3d ago
$115K - $165K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

13 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 13,975 patients
12 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)HIV Infection(75)